



# Instituto Ideia Fértil de Saúde Reprodutiva

Progenesis Brasil is honored to share our contribution at the Instituto Ideia Fertil de Saude Reprodutiva held on October 7th and 8th.



Dr. Nabil Arrach demonstrated the importance of data collection to improve outcomes and how the Progenesis Portal can play a key role in reducing the laboratory burden while serving as a tool for real-time decision making to provide patients with the highest chances of success.

Dr. Sheela Ali, presented Brazilian 2021 data outcome reported to Anvisa via SisEmbryo app. This can be compared as the equivalent of SART in the USA. The data was then analyzed and the importance of tracking KPIs in the laboratory was discussed to build and maintain the highest quality of patient care based on an effective Quality Management program. Variations in practice as they relate to outcome was also addressed.

Stay tuned for updates on our brand new PGT lab in Sao Paulo, Brasil!

Progenesis extends a special thanks and appreciation to **Dr. Emerson Barci Cordts** for organizing the successful symposium and welcoming our team to Brasil.


Pictured above is our Progenesis Brasil Team (from left to right): **Dr. Sheela Ali**-VP of Science and Innovation, **Pricilla Motta**-Director of QA and compliance, **Dr. Nabil Arrach** - CEO Progenesis, **Alex Mejia**-VP of Business Development Latin Americas, and **Dr. Fernanda Pacheco**, Brazilian REI partner.

## The Laboratory Impact on Mosaicism

Receiving a report with mosaic reads for a patient's biopsy can raise many concerns. What options does your center offer the patient when presented with a mosaic read? Do you know the rate of true positive mosaic embryos? It is expected to be < 0.5%. Have you considered re-biopsy of mosaic embryos? Progenesis offers re-biopsy at no additional charge for the patient. Contact us to discuss how this option can help your patients.

[support@progenesis.com](mailto:support@progenesis.com)

"If you can not measure it, you can not improve it"




Let's discuss this one-on-one with Progenesis and your whole team! Fill out this form for a complimentary webinar, open discussion and scheduled at your convenience for your whole team!  
<https://forms.gle/npxmemn2QW3KTPN16>

Visit Progenesis Academy for additional resources for continued education.



**Progenesis** is dedicated to the continued education in the reproductive community. Our poll of the month asks:



**Embryologists:** It is the last day of embryo culture and your patient has this embryo as the only available blastocyst for PGT consideration. What would you do?

- A. Biopsy at position #1. We would like to leave the highest quality of cells behind with the embryo so that we can maximize the chances for pregnancy.
- B. Biopsy at position #2. We would like to send the highest quality of cells for PGT so that we can obtain the most accurate result.
- C. Cancel the biopsy and vitrify only. Embryo has too few cells.
- D. Discard. Embryo is suboptimal quality and does not meet criteria for biopsy or vitrification.